Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLS NASDAQ:QTTB NASDAQ:SRZN NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.84+2.5%$3.12$2.27▼$5.48$284.96M2.8815,718 shs23,674 shsQTTBQ32 Bio$15.15-1.5%$12.33$1.57▼$23.57$256.88M0.242.60 million shs178,799 shsSRZNSurrozen$19.73-6.8%$23.87$8.70▼$35.00$229.07M0.51194,929 shs184,250 shsUPXIUpexi$0.80-0.7%$0.97$0.54▼$9.12$62.98M-0.291.45 million shs813,486 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+2.53%+7.98%+1.79%-26.99%+21.89%QTTBQ32 Bio-1.50%+0.66%+35.75%+143.57%+547.44%SRZNSurrozen-6.76%-10.15%-20.28%-29.89%+125.74%UPXIUpexi-0.73%-0.55%+1.29%-42.84%-88.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.84+2.5%$3.12$2.27▼$5.48$284.96M2.8815,718 shs23,674 shsQTTBQ32 Bio$15.15-1.5%$12.33$1.57▼$23.57$256.88M0.242.60 million shs178,799 shsSRZNSurrozen$19.73-6.8%$23.87$8.70▼$35.00$229.07M0.51194,929 shs184,250 shsUPXIUpexi$0.80-0.7%$0.97$0.54▼$9.12$62.98M-0.291.45 million shs813,486 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+2.53%+7.98%+1.79%-26.99%+21.89%QTTBQ32 Bio-1.50%+0.66%+35.75%+143.57%+547.44%SRZNSurrozen-6.76%-10.15%-20.28%-29.89%+125.74%UPXIUpexi-0.73%-0.55%+1.29%-42.84%-88.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 2.83Moderate Buy$7.00146.48% UpsideQTTBQ32 Bio 2.67Moderate Buy$22.3347.41% UpsideSRZNSurrozen 2.50Moderate Buy$42.00112.87% UpsideUPXIUpexi 2.33Hold$8.10912.25% UpsideCurrent Analyst Ratings BreakdownLatest UPXI, CLLS, SRZN, and QTTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026SRZNSurrozen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026QTTBQ32 Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $40.007/1/2026UPXIUpexi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$2.00 ➝ $1.306/29/2026SRZNSurrozen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/8/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/22/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$79.59M3.58N/AN/A$0.76 per share3.74QTTBQ32 Bio$53.74M4.78$1.52 per share9.99$3.41 per share4.44SRZNSurrozen$3.48M65.82N/AN/A($19.21) per share-1.03UPXIUpexi$15.81M3.98N/AN/A$1.01 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)QTTBQ32 Bio$29.82M$2.668.76N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)SRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%N/A-154.08%8/14/2026 (Estimated)UPXIUpexi-$13.68M-$0.62N/AN/AN/A-874.00%-66.70%-19.56%9/2/2026 (Estimated)Latest UPXI, CLLS, SRZN, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026SRZNSurrozen-$1.2880N/AN/AN/A$0.47 millionN/A8/11/2026H1 2026CLLSCellectis-$0.2630N/AN/AN/A$11.05 millionN/A8/5/2026Q2 2026QTTBQ32 Bio-$0.53N/AN/AN/A$1.00 millionN/A5/12/2026Q3 2026UPXIUpexi-$0.20-$1.67-$1.47-$1.67$2.90 million$1.05 million5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 million5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis1.131.521.52QTTBQ32 Bio0.045.365.36SRZNSurrozenN/A11.9111.91UPXIUpexi2.961.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%QTTBQ32 Bio31.32%SRZNSurrozen66.57%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%QTTBQ32 Bio34.46%SRZNSurrozen31.74%UPXIUpexi9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis290100.34 million83.87 millionOptionableQTTBQ32 Bio3916.96 million11.11 millionN/ASRZNSurrozen8011.61 million7.93 millionNot OptionableUPXIUpexi13078.70 million71.62 millionOptionableUPXI, CLLS, SRZN, and QTTB HeadlinesRecent News About These CompaniesUpexi (NASDAQ:UPXI) Shares Up 0.1% - Time to Buy?July 23 at 1:59 AM | marketbeat.comUpexi Insider Trading Activity | NASDAQ:UPXI | BenzingaJuly 7, 2026 | benzinga.comUpexi Inc: Upexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | finanznachrichten.deUpexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | globenewswire.comUpexi Added to Russell Microcap Index in June 2026 ReconstitutionJune 26, 2026 | quiverquant.comQUpexi Added to the Russell Microcap® IndexJune 26, 2026 | globenewswire.comUpexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common StockJune 22, 2026 | globenewswire.comUpexi Shareholders Reelect Board and Ratify AuditorJune 16, 2026 | tipranks.comUPXI Share News TodayMay 19, 2026 | uk.investing.comUpexi (UPXI) Stock Forecast & Price TargetMay 15, 2026 | investing.comUpexi Stock Short Interest Report | NASDAQ:UPXI | BenzingaMay 15, 2026 | benzinga.comUpexi (UPXI) Q3 2026 Earnings TranscriptMay 15, 2026 | fool.comUpexi, Inc. Earnings Call Highlights Crypto-Fueled VolatilityMay 13, 2026 | tipranks.comUpexi Net Loss Balloons to $109 Million on Solana Treasury MarkdownMay 13, 2026 | finance.yahoo.comUpexi Reports Fiscal Third Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comUpexi Q3 2026 earnings previewMay 11, 2026 | msn.comUpexi to Present at the LD Micro Invitational XVI Conference on May 17-19May 7, 2026 | globenewswire.comUpexi Provides Periodic Update to its Share Repurchase ProgramMay 6, 2026 | globenewswire.comUpexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ETMay 5, 2026 | globenewswire.comUpexi to Participate in the Scottsdale Capital Event on April 10-12March 31, 2026 | globenewswire.comUpexi to Participate in Upcoming March Investor ConferencesMarch 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, CLLS, SRZN, and QTTB Company DescriptionsCellectis NASDAQ:CLLS$2.84 +0.07 (+2.53%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.83 -0.01 (-0.35%) As of 07/24/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Q32 Bio NASDAQ:QTTB$15.15 -0.23 (-1.50%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$15.10 -0.05 (-0.33%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Surrozen NASDAQ:SRZN$19.73 -1.43 (-6.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.69 -0.04 (-0.20%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Upexi NASDAQ:UPXI$0.80 -0.01 (-0.73%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
